Načítá se...
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
The immune checkpoint inhibitors have significantly modified the therapeutic landscape of advanced non-small cell lung cancer in second-line and, more recently, first-line settings. Because of the superior outcome with pembrolizumab as an upfront strategy, PD-L1 status should now be considered a new...
Uloženo v:
| Vydáno v: | BMC Med |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5346853/ https://ncbi.nlm.nih.gov/pubmed/28285592 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-017-0819-3 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|